Centre for Ecological and Evolutionary Research on Cancer (CREEC), MIVEGEC, IRD, CNRS, Univ. Montpellier, Montpellier, France.
Centre for Integrative Ecology, School of Life and Environmental Sciences, Deakin University, Waurn Ponds, VIC, Australia.
BMC Evol Biol. 2018 Dec 6;18(1):185. doi: 10.1186/s12862-018-1298-7.
A strong variability in cancer incidence is observed between human organs. Recently, it has been suggested that the relative contribution of organs to organism fitness (reproduction or survival) could explain at least a part of the observed variation. The objective of this study is to investigate theoretically the main factors driving the evolution of tumour resistance mechanisms of organs when their relative contribution to organism fitness is considered. We use a population-scale model where individuals can develop a tumour in a key organ (i.e. in which even a small tumour can negatively impact organism fitness), an auxiliary organ (i.e. in which only a large tumour has a relatively significant impact) or both organs because of metastasis.
Our simulations show that natural selection acts in two different ways to prevent cancer in a key and an auxiliary organs. In the key organ, the strategy mostly selected is the highest resistance and only a high cost of resistance mitigates this behavior. Inversely, we observe that a low resistance strategy can be selected in the auxiliary organ when the development of the tumour is slow and the effect of a large tumour on the mortality of the organism is relatively weak. Nevertheless, if the tumour can spread to a key organ, higher resistance strategies are selected in the auxiliary organ.
Finally, our study demonstrates that the relative contribution of organs to the organism fitness and the metastatic propensity of the tumour influence the evolution of tumour resistance at organ scale and should be considered by studies aiming to explain the variability in cancer incidence at organ-scale.
人类器官之间的癌症发病率存在很强的可变性。最近,有人提出,器官对机体适应性(繁殖或生存)的相对贡献至少可以解释部分观察到的变异。本研究的目的是理论上探讨当考虑器官对机体适应性的相对贡献时,驱动肿瘤抵抗机制进化的主要因素。我们使用一种基于群体的模型,其中个体可以在关键器官(即即使是小肿瘤也会对机体适应性产生负面影响的器官)、辅助器官(即只有大肿瘤才会产生相对显著影响的器官)或两者中发展肿瘤,因为转移。
我们的模拟表明,自然选择以两种不同的方式在关键器官和辅助器官中防止癌症。在关键器官中,选择的主要策略是最高的抵抗性,只有高抵抗性成本才能减轻这种行为。相反,当肿瘤生长缓慢且大肿瘤对机体死亡率的影响相对较弱时,我们观察到辅助器官中可以选择低抵抗性策略。然而,如果肿瘤可以扩散到关键器官,则辅助器官中会选择更高的抵抗性策略。
最后,我们的研究表明,器官对机体适应性的相对贡献和肿瘤的转移倾向影响肿瘤抵抗在器官水平上的进化,这应该在旨在解释器官水平上癌症发病率变异性的研究中加以考虑。